Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Lamb

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Experimental Hematology|January 22, 2005
Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonistConnie L Erickson-Miller, Evelyne DeLorme, Shin-Shay Tian, et al.
Molecular Cancer Therapeutics|November 18, 2022
Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MERJeff Hsu, Colin Chong, Jeffrey Serrill, et al.
Thyroid : Official Journal of the American Thyroid Association|May 28, 2013
In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancerFrauke Bentzien, Marcus Zuzow, Nathan Heald, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2008
EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformationTorsten Trowe, Sotiria Boukouvala, Keith Calkins, et al.
Journal of Medicinal Chemistry|August 9, 2002
Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 1. Discovery and optimization of salicylaldehyde thiosemicarbazone thrombopoietin mimicsKevin J Duffy, Anthony N Shaw, Evelyne Delorme, et al.
The Journal of Biological Chemistry|January 14, 2003
Selective binding and oligomerization of the murine granulocyte colony-stimulating factor receptor by a low molecular weight, nonpeptidyl ligandMichael L Doyle, Shin-Shay Tian, Stephen G Miller, et al.
Journal of Medicinal Chemistry|August 9, 2002
Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 2. Rational design of naphtho[1,2-d]imidazole thrombopoietin mimicsKevin J Duffy, Alan T Price, Evelyne Delorme, et al.
Bioorganic & Medicinal Chemistry Letters|October 7, 2011
Discovery of a new class of glucosylceramide synthase inhibitorsElena Koltun, Steven Richards, Vicky Chan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 9, 2020
Uncovering Infant Group B Streptococcal (GBS) Disease Clusters in the United Kingdom and Ireland Through Genomic Analysis: A Population-based Epidemiological StudySimon M Collin, Natalie Groves, Catherine O'Sullivan, et al.
Journal of Medicinal Chemistry|January 5, 2012
Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonistsMohamed A Ibrahim, Henry W B Johnson, Joon Won Jeong, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Experimental Hematology|January 22, 2005
Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonistConnie L Erickson-Miller, Evelyne DeLorme, Shin-Shay Tian, et al.
Molecular Cancer Therapeutics|November 18, 2022
Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MERJeff Hsu, Colin Chong, Jeffrey Serrill, et al.
Thyroid : Official Journal of the American Thyroid Association|May 28, 2013
In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancerFrauke Bentzien, Marcus Zuzow, Nathan Heald, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2008
EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformationTorsten Trowe, Sotiria Boukouvala, Keith Calkins, et al.
Journal of Medicinal Chemistry|August 9, 2002
Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 1. Discovery and optimization of salicylaldehyde thiosemicarbazone thrombopoietin mimicsKevin J Duffy, Anthony N Shaw, Evelyne Delorme, et al.
The Journal of Biological Chemistry|January 14, 2003
Selective binding and oligomerization of the murine granulocyte colony-stimulating factor receptor by a low molecular weight, nonpeptidyl ligandMichael L Doyle, Shin-Shay Tian, Stephen G Miller, et al.
Journal of Medicinal Chemistry|August 9, 2002
Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 2. Rational design of naphtho[1,2-d]imidazole thrombopoietin mimicsKevin J Duffy, Alan T Price, Evelyne Delorme, et al.
Bioorganic & Medicinal Chemistry Letters|October 7, 2011
Discovery of a new class of glucosylceramide synthase inhibitorsElena Koltun, Steven Richards, Vicky Chan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 9, 2020
Uncovering Infant Group B Streptococcal (GBS) Disease Clusters in the United Kingdom and Ireland Through Genomic Analysis: A Population-based Epidemiological StudySimon M Collin, Natalie Groves, Catherine O'Sullivan, et al.
Journal of Medicinal Chemistry|January 5, 2012
Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonistsMohamed A Ibrahim, Henry W B Johnson, Joon Won Jeong, et al.
Pageof 5